(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Ariana Grande and Jonathan Bailey will reunite for 'Sunday in the Park With George' - 2German foreign minister heads to China to talk rare-earth exports
- 3When fake data is a good thing – how synthetic data trains AI to solve real problems
- 4Regeneron's experimental therapy combo effective in untreated cancer patients
- 5CDC studies show value of nationwide wastewater disease surveillance, as potential funding cut looms
- Here's what can happen if you drive under the influence of pot
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
- Kelsey Grammer on having a new baby at 70: 'You're just more available now'
- The most effective method to Recognize a Great Lab Jewel
- Tasting America: An Excursion Through Darling Cheap Food Brands
- Poll: Only 25% of Americans think Trump has 'followed through' on his promise to release the Epstein files
- Lower-cost space missions like NASA's ESCAPADE are starting to deliver exciting science – but at a price in risk and trade‑offs
- Favored Chinese Dish: Make Your Determination
